Impact on Quality of Life, Fatigue and Cognitive Function in Anti-angiogenesis in Patients With Metastatic Kidney Cancer (COG-ANGIO)

Centre Francois Baclesse

Status: Terminated

Conditions: Metastatic Kidney Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01336231

COG-ANGIO

Details and patient eligibility

About

Longitudinal study nonrandomized, multicenter observational descriptive monitoring patients treated with anti-angiogenic for metastatic kidney cancer

Enrollment: 82 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient (e) Age (e) over 18 years
• Kidney cancer metastatic or locally advanced
• Anti-angiogenic or targeted therapy (bevacizumab, sorafenib, sunitinib, temsirolimus, another molecule or developing or having obtained authorization in this indication) may be associated with interferon or combined together
• Proposed treatment in first line or second line
• Brain imaging not finding brain metastases
• Having signed the informed consent of study participation
• The patient may have received prior anti-angiogenic

Exclusion criteria

• Cancer of the kidney other than primitive
• Previous history of cancer other than kidney cancer in complete remission for less than 5 years
• Patients under 18 years
• Patients whose treatment is associated with chemotherapy
• disorders of cognitive functions to existing treatment delivery
• Pathology psychiatric evolutionary
• Refusal of participation
• Patient unable to respond to cognitive tests
• Drug use
• Heavy drinking (WHO criteria)
• History of stroke
• History of head trauma
• Brain metastases known
• MMS below normal compared to existing standards for age and socio-cultural

Trial design

82 participants in 1 patient group

patients group

Description:

Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic